Drugs / Isatuximab SAR650984
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03637764 | Aug 2018 → May 2022 | neoplasm | Sanofi | Terminated | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT04270409 | Jun 2020 → Oct 2030 expected | plasma cell myeloma | Sanofi | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Isatuximab SAR650984 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04270409 ↗ |
| Route | Intravenous | “Route of administration: intravenous” NCT03637764 ↗ |